title: Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia.
abstract: The long-term follow-up is presented for 317 patients with acute myeloid leukaemia who underwent human leucocyte antigen-identical sibling marrow transplants between 1984 and 1995 following preparation with busulfan 16 mg/kg and cyclophosphamide 120 mg/kg. Among the 142 (45%) who were alive and leukaemia-free 3 years following transplantation, the leukaemia-free survival at 15 years was 72.8%. The cumulative incidence of late (>3 years beyond transplant) non-relapse mortality at 15 years was 12.9% and of late relapse was 16.5%. None of the variables considered (including age, disease stage, and graft-versus-host disease) were predictive of late failure.
authors.affiliation: Division of Haematology/Oncology, The Ohio State University, Columbus, OH, USA.
authors.forename: Shubham
authors.initials: S
authors.lastname: Pant
authors.forename: Mehdi
authors.initials: M
authors.lastname: Hamadani
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Dodds
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Szer
authors.forename: Pamela A
authors.initials: PA
authors.lastname: Crilley
authors.forename: Dustin
authors.initials: D
authors.lastname: Stevenson
authors.forename: Gary
authors.initials: G
authors.lastname: Phillips
authors.forename: Patrick
authors.initials: P
authors.lastname: Elder
authors.forename: Ian
authors.initials: I
authors.lastname: Nivison-Smith
authors.forename: Belinda R
authors.initials: BR
authors.lastname: Avalos
authors.forename: Sam
authors.initials: S
authors.lastname: Penza
authors.forename: David
authors.initials: D
authors.lastname: Topolsky
authors.forename: Ronald
authors.initials: R
authors.lastname: Sobecks
authors.forename: Matt
authors.initials: M
authors.lastname: Kalaycio
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Bolwell
authors.forename: Edward A
authors.initials: EA
authors.lastname: Copelan
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016465:Bone Marrow Purging / Q000379:methods; D002066:Busulfan / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004812:Epidemiologic Methods; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan